Epigral Ltd (IN:EPIGRAL)
:EPIGRAL
Want to see IN:EPIGRAL full AI Analyst Report?
EPIGRAL Stock Chart & Stats
₹1244.30
-₹4.30(-0.24%)
At close: 4:00 PM EST
₹1244.30
-₹4.30(-0.24%)
Day’s Range― - ―
52-Week Range₹806.20 - ₹2,114.30
Previous CloseN/A
Volume42.70K
Average Volume (3M)1.86K
Market Cap
₹51.62B
Enterprise Value₹56.76B
Total Cash (Recent Filing)₹485.70M
Total Debt (Recent Filing)₹5.37B
Price to Earnings (P/E)33.6
Beta1.49
Next Earnings
May 02, 2026EPS Estimate
14.3Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)9.10
Shares Outstanding43,141,340
10 Day Avg. Volume1,295
30 Day Avg. Volume1,859
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)4.21
Price to Sales (P/S)3.14
P/FCF Ratio32.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)65.75
Revenue Forecast (FY)₹28.31B
Bulls Say, Bears Say
Bulls Say
Healthy MarginsSustained healthy gross, EBIT and EBITDA margins indicate structural pricing power and operational efficiency in core chlor-alkali and downstream businesses, supporting durable profitability across cycles and enabling reinvestment even if volumes fluctuate over the next 2–6 months.
Improved Free Cash FlowThe move from negative to positive free cash flow with strong operating cash conversion shows the company can generate internal funds for capex, debt servicing or tactical growth. This improves financial flexibility and reduces reliance on external funding over the medium term.
Stronger Balance Sheet MetricsAn improved debt-to-equity ratio and solid ROE reflect healthier leverage management and effective use of capital. A stronger equity base enhances resilience to downturns and supports strategic investments or downstream integration initiatives over the coming quarters.
Bears Say
Substantial Total DebtMaterial absolute debt creates ongoing fixed obligations and interest exposure; in a cyclical chemical sector this can constrain capital allocation, force tighter liquidity management, and amplify downside risk if cash generation weakens or input costs spike over the next several months.
Volatile Revenue GrowthInconsistent top-line performance complicates capacity planning and margin predictability for a commodities-linked producer. Revenue swings can pressure utilization-dependent economics and make multi-quarter forecasting and investment decisions more uncertain for management and investors.
Input-cost SensitivityHeavy exposure to power and salt costs and spreads between inputs and product prices creates structural margin risk. Energy and raw material price moves or disruptions can materially compress margins and cash flow, reducing predictability across the medium term.
Epigral Ltd News
EPIGRAL FAQ
What was Epigral Ltd’s price range in the past 12 months?
Epigral Ltd lowest stock price was ₹806.20 and its highest was ₹2114.30 in the past 12 months.
What is Epigral Ltd’s market cap?
Epigral Ltd’s market cap is ₹51.62B.
When is Epigral Ltd’s upcoming earnings report date?
Epigral Ltd’s upcoming earnings report date is May 02, 2026 which is tomorrow.
How were Epigral Ltd’s earnings last quarter?
Epigral Ltd released its earnings results on Jan 30, 2026. The company reported ₹9.1 earnings per share for the quarter, beating the consensus estimate of ₹7.3 by ₹1.8.
Is Epigral Ltd overvalued?
According to Wall Street analysts Epigral Ltd’s price is currently Overvalued.
Does Epigral Ltd pay dividends?
Epigral Ltd pays a Semiannually dividend of ₹3.5 which represents an annual dividend yield of 0.46%. See more information on Epigral Ltd dividends here
What is Epigral Ltd’s EPS estimate?
Epigral Ltd’s EPS estimate is 14.3.
How many shares outstanding does Epigral Ltd have?
Epigral Ltd has 43,141,340 shares outstanding.
What happened to Epigral Ltd’s price movement after its last earnings report?
Epigral Ltd reported an EPS of ₹9.1 in its last earnings report, beating expectations of ₹7.3. Following the earnings report the stock price went up 0.894%.
Which hedge fund is a major shareholder of Epigral Ltd?
Currently, no hedge funds are holding shares in IN:EPIGRAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Epigral Ltd
Epigral Limited manufactures and sells chlor-alkali and related derivatives in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resins, epichlorohydrin, chloromethanes, hydrogen peroxide, caustic soda, chlorine, hydrogen, and caustic potash products. It also trades in agrochemical products. The company serves various sectors, including CPVC pipes and fittings, windmills, construction, paints and coatings, electronics, water treatment, agrochemicals, pharmaceuticals, refineries, soap and detergents, fluoropolymers, paper and pulp, textiles, alumina, polyurethane foam, lithium, and polytetrafluoroethylene (PTFE) pipes. The company was formerly known as Meghmani Finechem Limited and changed its name to Epigral Limited in August 2023. Epigral Limited was incorporated in 2007 and is based in Ahmedabad, India.
Technical Analysis
Gufic Biosciences Limited
―
Marksans Pharma Limited
―
Shilpa Medicare Limited
―
Strides Pharma Science Ltd
―
Supriya Lifescience Limited
―